Immuneering Corp (IMRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $240.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Immuneering Corp (IMRX) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Immuneering reported EPS of -$0.37, below the -$0.29 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IMRX's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
IMRX Earnings Call
The latest IMRX earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, IMRX beat 13, missed 9 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 137.78% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.37 | -$0.29 | -$0.37 - -$0.27 | -27.59% | Miss | N/A | 7 | 1 up, 2 down | Oct 29, 2026 | N/A |
| Jun 30, 2026 | -$0.27 | -$0.26 | -$0.31 - -$0.24 | -3.85% | Miss | N/A | 7 | 2 up, 2 down | Aug 5, 2026 | N/A |
| Mar 31, 2026 | -$0.21 | -$0.35 | N/A | +40.00% | Beat | N/A | 5 | 3 up, 0 down | May 15, 2026 | N/A |
| Dec 31, 2025 | -$0.18 | -$0.31 | -$0.37 - -$0.23 | +41.94% | Beat | N/A | 6 | N/A | Mar 6, 2026 | N/A |
| Sep 30, 2025 | -$0.38 | -$0.39 | -$0.48 - -$0.29 | +2.56% | Beat | N/A | 6 | 2 up, 2 down | Nov 12, 2025 | N/A |
| Jun 30, 2025 | -$0.40 | -$0.40 | -$0.48 - -$0.30 | 0.00% | In line | N/A | 5 | 1 up, 0 down | Aug 13, 2025 | N/A |
| Mar 31, 2025 | -$0.42 | -$0.58 | -$0.66 - -$0.51 | +27.59% | Beat | N/A | 2 | 1 up, 0 down | May 5, 2025 | N/A |
| Dec 31, 2024 | -$1.07 | -$0.45 | -$0.73 - -$0.23 | -137.78% | Miss | N/A | 4 | 0 up, 0 down | Mar 20, 2025 | $726326 |
| Sep 30, 2024 | -$0.49 | -$0.55 | -$0.60 - -$0.49 | +10.91% | Beat | N/A | 7 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$0.47 | -$0.53 | -$0.56 - -$0.47 | +11.32% | Beat | N/A | 6 | 0 up, 0 down | Aug 6, 2024 | N/A |
| Mar 31, 2024 | -$0.49 | -$0.50 | -$0.59 - -$0.22 | +2.00% | Beat | N/A | 7 | 0 up, 0 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$0.52 | -$0.47 | -$0.53 - -$0.37 | -10.64% | Miss | N/A | 9 | 1 up, 0 down | Mar 1, 2024 | N/A |
| Sep 30, 2023 | -$0.43 | -$0.49 | -$0.56 - -$0.44 | +12.24% | Beat | N/A | 8 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.43 | -$0.53 | -$0.62 - -$0.48 | +18.87% | Beat | N/A | 8 | 0 up, 0 down | Aug 3, 2023 | N/A |
| Mar 31, 2023 | -$0.51 | -$0.56 | -$0.63 - -$0.52 | +8.93% | Beat | N/A | 8 | 0 up, 0 down | May 4, 2023 | N/A |
| Dec 31, 2022 | -$0.50 | -$0.58 | -$0.61 - -$0.54 | +13.79% | Beat | N/A | 7 | 0 up, 0 down | Mar 6, 2023 | $455 |
| Sep 30, 2022 | -$0.49 | -$0.48 | -$0.54 - -$0.41 | -2.08% | Miss | N/A | 6 | 0 up, 0 down | Nov 10, 2022 | $38380 |
| Jun 30, 2022 | -$0.44 | -$0.52 | -$0.54 - -$0.50 | +15.38% | Beat | N/A | 7 | 0 up, 0 down | Aug 10, 2022 | $94419 |
| Mar 31, 2022 | -$0.49 | -$0.44 | -$0.46 - -$0.43 | -11.36% | Miss | N/A | 6 | 0 up, 0 down | May 10, 2022 | $183698 |
| Dec 31, 2021 | -$0.42 | -$0.39 | -$0.47 - -$0.32 | -7.69% | Miss | N/A | 5 | 0 up, 0 down | Mar 10, 2022 | $189591 |
| Sep 30, 2021 | -$0.47 | -$0.62 | -$0.73 - -$0.46 | +24.19% | Beat | N/A | 4 | N/A | Nov 9, 2021 | $482130 |
| Jun 30, 2021 | -$1.61 | -$1.44 | -$1.94 - -$0.79 | -11.81% | Miss | N/A | 3 | N/A | Jul 30, 2021 | $660040 |
| Mar 31, 2021 | -$1.26 | -$1.25 | N/A | -0.80% | Miss | N/A | N/A | N/A | Jun 2, 2021 | $748200 |
| Dec 31, 2020 | -$1.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $665080 |
| Dec 31, 2019 | -$0.65 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.38, after -$2.52 the year before. It was -$0.65 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.38 | N/A |
| Dec 31, 2024 | -$2.52 | N/A |
| Dec 31, 2023 | -$1.89 | N/A |
| Dec 31, 2022 | -$1.92 | N/A |
| Dec 31, 2021 | -$3.76 | N/A |
| Dec 31, 2020 | -$1.26 | N/A |
| Dec 31, 2019 | -$0.65 | N/A |
Earnings Calls
The only earnings call listed below, 2025Q3 for the period ended Sep 30, 2025, runs about 5,600 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 5,562 | 10 |
2025Q3 Earnings Call
Opening remarks
Laurence Watts Investor Relations Thank you, Operator. Joining us on the call today from Immuneering Corporation are Chief Executive Officer, Benjamin Zeskind, Chief Scientific Officer, Brett Hall, Chief Medical Officer, Igor Marchanski, Chief Accounting Officer and Treasurer, Mallory Morales, and Ibi Brakewood, our Chief Business Officer.
Benjamin Zeskind CEO During this call, management and our two investigators will refer to slides you can find in the updated version of our corporate deck available in PDF on our IR website. Throughout this call, management will be making forward-looking statements, including statements related to its Phase IIa trial of atezvastib as well as the timing of additional data from the study and the company's development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties. Factors that could cause these results to be different from these statements include factors the company describes in its security filings, including its annual report on Form 10-Ks and our quarterly reports on Form 10-Q. Immuneering Corporation undertakes no duty or obligation to update any forward statements as a result of new information, future events, or changes in its expectations. With that, I will turn the call over to Benjamin Zeskind, Chief Executive Officer of Immuneering Corporation. Ben? Thank you, Laurence. Good afternoon, everyone, and thank you for your interest in Immuneering Corporation. We do not always hold quarterly calls, but we try to do so when we have something interesting to share. And today, we are very fortunate to be joined by two investigators from our Phase 2a trial, who will walk us through two remarkable case studies of first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX. The investigators are Dr. Allison J. Ocean, Professor of Clinical Medicine at the Weill Medical College of Cornell University, and Dr. Gregory Bata, Associate Professor of Medicine at the Moores Cancer Center at UC San Diego. Doctors are, of course, busy individuals who plan to start the call with their respective case studies, after which we will let them get back to their patients. Then we will share a summary of the third quarter and why it was so transformational for Immuneering Corporation. In September, we shared an update on 34 first-line pancreatic cancer patients treated with atebimetinib in combination with gemcitabine nab-paclitaxel, with remarkable overall survival. We are as excited as ever about the overall survival we are seeing in that cohort, and we are very excited to share an update soon. We are currently planning to do so in 2026, possibly at a major medical meeting.
Frequently Asked Questions About IMRX
Did IMRX beat earnings estimates last quarter?
No. Immuneering reported EPS of -$0.37 for the quarter ended Sep 30, 2026, below the -$0.29 estimate by 27.59%.
What EPS do analysts expect from IMRX next quarter?
The consensus EPS estimate for Immuneering for the quarter ending Dec 31, 2026 is -$0.35 from 9 analysts, with estimates from -$0.44 to -$0.30.
How often does IMRX beat earnings estimates?
Immuneering beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -7.14%.
IMRX pages: Overview, Earnings, Forecast, Financials, Competitors